BioMarin Announced Positive Final Results from Vosoritide Phase 3 pivotal trial. (BMN111-301) BioMarin
BioMarin Announces Cumulative Additional Height Gain of 9.0 cm over 54 months versus Natural History in Children with Achondroplasia Treated with Vosoritide in Phase 2 Study BioMarin
BioMarin Doses First Participant in Phase 2 Study of Vosoritide for Treatment of Infants and Young Children with Achondroplasia BioMarin
